Skip to main content

Explore our strategy and projects
to learn about the future of our company

Results FY 2022 (€/MLN)

Learn more

1,361

Revenues

514

Adjusted EBITDA

319

Adjusted net profit

316

Free cash flow

Stock price

Discover more

Press releases

06/11/23 - 15:44

Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market
Download

03/11/23 - 15:51

Price sensitive
Third Quarter results confirm guidance for Fiscal Year 2023
Download
Learn More

Presentations

03/11/23

9M 2023 Results Presentation
Download presentation
Learn More
Calendar

Calendar

Jefferies - London Healthcare Conference

London

IR

Event expired
View all

Keep
in touch

Sign up for our investor alerts
and stay informed
on the latest developments

Privacy Statement *
The Undersigned Confirms That The Information. Provided Pursuant To Leg. Decree No. 196/2003 Has Been Read And Accepted.